openPR Logo
Press release

Myelodysplastic Syndrome (MDS) Drugs Market Size, Scope Analysis, Key Insights, Leading Key Players, And Forecast To 2033

08-12-2024 11:16 AM CET | Health & Medicine

Press release from: The Business Research Company

Myelodysplastic Syndrome (MDS) Drugs Market Size

Myelodysplastic Syndrome (MDS) Drugs Market Size

"The new report published by The Business Research Company, titled Myelodysplastic Syndrome (MDS) Drugs Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the myelodysplastic syndrome (mds) drugs market size has grown strongly in recent years. It will grow from $3.23 billion in 2023 to $3.47 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The myelodysplastic syndrome (mds) drugs market size is expected to see strong growth in the next few years. It will grow to $4.69 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=13043&type=smp

Elevated Cancer Treatment Exposure Accelerates Growth In The Myelodysplastic Syndrome (MDS) Drug Market
Rising exposure to cancer treatments, such as chemotherapy and radiation, is expected to boost the growth of the myelodysplastic syndrome (MDS) drug market going forward. Chemotherapy refers to using medications to eradicate cancer cells and radiation refers to a cancer treatment that uses high radiation doses to kill cancer cells and reduce tumors. Chemotherapy medications and radiation therapy harm the bone marrow's stem cells, which are in charge of making new blood cells; this damaging effect disturbs the natural balance of cell creation and results in the onset of MDS. Myelodysplastic syndrome (MDS) drugs offer several benefits in managing and treating MDS, a group of disorders characterized by abnormal production of blood cells in the bone marrow. For instance, according to ESTRO-HERO (Health Economics in Radiation Oncology) analysis by the European Society of Radiation Oncology (ESTRO), a Belgium-based organization, based on projected cancer distributions in 2025, there is an expected 16% increase in the number of radiotherapy treatment courses. Therefore, rising exposure to cancer treatments, such as chemotherapy and radiation, is driving the growth of the myelodysplastic syndrome (MDS) drugs market.

Innovative Drug Development And Approvals Transform Myelodysplastic Syndrome (MDS) Treatment Market
Major companies operating in the myelodysplastic syndrome (MDS) drugs market focus on developing new products to improve patient outcomes, meet specific customer needs and fit the ecosystem. Drug approvals such as venetoclax (VENCLEXTA) ensure that MDS drugs are safe and effective for managing this group of bone marrow disorders. For instance, in July 2021, AbbVie Inc., a US-based pharmaceutical company, received a Breakthrough Therapy Designation (BTD) for venetoclax (VENCLEXTA) in combination with azacitidine by the U.S. Food and Drug Administration (FDA) for the potential treatment of adult patients with untreated intermediate, high and very high-risk myelodysplastic syndromes (MDS). The unique feature of VENCLEXTA and VENCLYXTO is its capacity to attach to and inhibit the B-cell lymphoma-2 (BCL-2) protein. Additionally, BCL-2 inhibits the apoptosis, or natural death or self-destruction process of cancer cells, in several blood malignancies.

The myelodysplastic syndrome (mds) drugs market covered in this report is segmented -

1) By Drug Type: Chemotherapy; Immunomodulatory Drugs
2) By Route Of Administration: Oral; Parenteral
3) By Syndrome: Refractory Cytopenia With Multilineage Dysplasia; Refractory Anemia; Refractory Anemia With Ringed Sideroblasts
4) By End User: Hospitals; Clinics; Ambulatory Surgical Centers

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=13043&type=discount

Major players in the myelodysplastic syndrome (mds) drugs market are Bristol Myers Squibb, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma Inc., Aprea Therapeutics, Onconova Therapeutics Inc., Geron Corporation, Amgen Inc., Sandoz, Gilead Sciences Inc., Johnson And Johnson, Lupin Ltd. Corporation, Ono Pharmaceutical Co. Ltd., Eisai Co. Ltd., Nippon Shinyaku Co. Ltd., Lupin Ltd., Accord Healthcare Inc., Kite Pharma Inc., Karyopharm Therapeutics Inc., Aprea Therapeutics Inc., Acceleron Pharma Inc., Astex Pharmaceuticals Inc., Stemline Therapeutics Inc., Geron Corporation, Onconova Therapeutics Inc., Actinium Pharmaceuticals Inc., Millennium Pharmaceuticals Inc.

Contents of the report:
1. Executive Summary
2. Myelodysplastic Syndrome (MDS) Drugs Market Report Structure
3. Myelodysplastic Syndrome (MDS) Drugs Market Trends And Strategies
4. Myelodysplastic Syndrome (MDS) Drugs Market - Macro Economic Scenario
5. Myelodysplastic Syndrome (MDS) Drugs Market Size And Growth
…..
27. Myelodysplastic Syndrome (MDS) Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-mds-drugs-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Myelodysplastic Syndrome (MDS) Drugs Market Size, Scope Analysis, Key Insights, Leading Key Players, And Forecast To 2033 here

News-ID: 3619277 • Views:

More Releases from The Business Research Company

Company Registration Service Market Landscape 2025: Forecast Data and Growth Strategy Insights
Company Registration Service Market Landscape 2025: Forecast Data and Growth Str …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Company Registration Service Market Through 2025? The market size for company registration services has seen robust growth in the recent past. The market is projected to expand from $10.67 billion in 2024 to $11.55 billion in 2025, exhibiting a compound annual growth
Comprehensive 2025 Commercial Toilet Partition Market Overview: Trends, Forecasts, and Growth Drivers
Comprehensive 2025 Commercial Toilet Partition Market Overview: Trends, Forecast …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Commercial Toilet Partition Market Through 2025? In recent years, the market size for commercial toilet partitions has significantly expanded. The forecast predicts a rise from $1.82 billion in 2024 to $1.95 billion in 2025, with a compound annual growth rate (CAGR) of
Key Trends Influencing the Growth of the Commercial Insurance For Small And Medium-Sized Enterprises (SMEs) Market in 2025: Advancement In Digital Insurance Platforms Transforms Small And Medium Enterprises Coverage With Integrated, Data-Driven Solutions
Key Trends Influencing the Growth of the Commercial Insurance For Small And Medi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Commercial Insurance For Small And Medium-Sized Enterprises (SMEs) Market Through 2025? The market size of commercial insurance for small and medium-sized enterprises (SMEs) has seen substantial growth over the recent years. A rise from $111.83 billion in 2024 to $119.76 billion in
Growing Focus On Reducing Greenhouse Gas Emissions Driving The Market Growth Due To Rising Environmental Monitoring Requirements: Strengthening the Growth Trajectory of the Combustion Emissions Analyzer Market
Growing Focus On Reducing Greenhouse Gas Emissions Driving The Market Growth Due …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Combustion Emissions Analyzer Market Through 2025? In the past few years, the market size for combustion emissions analyzer has seen robust growth. It is projected to increase from $1.02 billion in 2024 to $1.09 billion in 2025, with a compound annual growth

All 5 Releases


More Releases for MDS

Prominent Myelodysplastic Syndrome (MDS) Drugs Market Trend for 2025: Innovative …
What Are the Projected Growth and Market Size Trends for the Myelodysplastic Syndrome (MDS) Drugs Market? The myelodysplastic syndrome (MDS) drugs market has expanded steadily in recent years. It is projected to increase from $3.47 billion in 2024 to $3.73 billion in 2025, reflecting a CAGR of 7.5%. The past growth can be attributed to the aging population, advancements in targeted therapies, ongoing clinical trials, and increased awareness. The myelodysplastic syndrome (MDS)
Myelodysplastic Syndrome (MDS) Treatment Market Insights, Forecast to 2031
"Myelodysplastic Syndrome (MDS) Treatment Market 2024," The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Myelodysplastic Syndrome (MDS) Treatment market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Myelodysplastic Syndrome (MDS) Treatment industry, providing stakeholders
MDS Dental Assisting Academy Brings Flexible Dental Assisting Courses Online
CONTACT: MDS Dental Assisting Academy Address: 122 Thicket Lane City: Freedom State: California Postcode: 95019 Country: USA Telephone: 1-888-637-4732 Website: https://dentalassistanceschool.com/ Email: info@mds4rda.com California, January 28th, 2022: Are you interested in dentistry? What do you think of a career in dental assisting? If being a dental assistant is your career choice, then an RDA program in MDS Dental Assisting Academy will suit you the best. They provide an interactive course
CASwell Secures Products Against MDS Attacks
New firmware updates for network devices & servers against ZombieLoad, RIDL & Fallout Taipei, Taiwan - August 27th, 2019 - CASwell Inc., a leading manufacturer of innovative and high-performance server solutions for SD-WAN (uCPE/vCPE) and network security systems, announced today that most of its network devices and servers have received updates for their firmware or BIOS making them secure against any malicious attacks based on MDS vulnerabilities. With these updates customers
Myeloidysplastic Syndromes (MDS) – Epidemiology Insights (2016-2028)
Myeloidysplastic syndromes (MDS) can be described as a group of hematologic malignancies, that occurr due to abnormality in blood-forming cells in the bone marrow. It is a rare blood cancer and can be mild, moderate or severe, in terms of severity. Download the sample report @ https://www.pharmaproff.com/request-sample/1162 This syndrome can be classified into three main types: MDS with single lineage dysplasia wherein a single type of blood cell appears abnormal; multilineage
Myelodysplastic Syndrome (MDS) Treatment Market Industry Forecast till 2025
Myelodysplastic (MDS) syndrome is a type of bone marrow disorder, where bone marrow is unable to produce healthy and mature blood cells. The immature blood cells called as blasts, get stored in the bone marrow and blood and obstruct the natural function of the hematological system which results in depletion of healthy red blood cells, platelets, and white blood cells. Myelodysplastic syndrome is usually seen in geriatric population and more